CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...

The nasal spray can be given to people who haven’t seen improvements in their depression after taking at least two oral medications, according to Johnson & Johnson. The main ingredient for the spray ...

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.

Nandita Vijayasimha, Bengaluru Thursday, February 6, 2025, 08:00 Hrs [IST] ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.